Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Sarkis K. Mazmanian | M | - |
Symbiotix Biotherapies, Inc.
 Symbiotix Biotherapies, Inc. BiotechnologyHealth Technology Symbiotix Biotherapies, Inc. develops a novel class of molecular therapeutics based on the human microbiome. It delivers first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. The company was founded by Lloyd Kasper, Nader Yaghoubi, Sarkis Mazmanian and Dennis Kasper in 2009 and is headquartered in Boston, MA. | 15 ans |
| Peter Alff | M | - |
Symbiotix Biotherapies, Inc.
Symbiotix Biotherapies, Inc. BiotechnologyHealth Technology Symbiotix Biotherapies, Inc. develops a novel class of molecular therapeutics based on the human microbiome. It delivers first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. The company was founded by Lloyd Kasper, Nader Yaghoubi, Sarkis Mazmanian and Dennis Kasper in 2009 and is headquartered in Boston, MA. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Nader Yaghoubi | M | - |
Symbiotix Biotherapies, Inc.
Symbiotix Biotherapies, Inc. BiotechnologyHealth Technology Symbiotix Biotherapies, Inc. develops a novel class of molecular therapeutics based on the human microbiome. It delivers first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. The company was founded by Lloyd Kasper, Nader Yaghoubi, Sarkis Mazmanian and Dennis Kasper in 2009 and is headquartered in Boston, MA. | - |
| Sheila Mikhail | F | 57 |
Symbiotix Biotherapies, Inc.
Symbiotix Biotherapies, Inc. BiotechnologyHealth Technology Symbiotix Biotherapies, Inc. develops a novel class of molecular therapeutics based on the human microbiome. It delivers first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. The company was founded by Lloyd Kasper, Nader Yaghoubi, Sarkis Mazmanian and Dennis Kasper in 2009 and is headquartered in Boston, MA. | - |
| Lloyd Kasper | M | - |
Symbiotix Biotherapies, Inc.
Symbiotix Biotherapies, Inc. BiotechnologyHealth Technology Symbiotix Biotherapies, Inc. develops a novel class of molecular therapeutics based on the human microbiome. It delivers first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. The company was founded by Lloyd Kasper, Nader Yaghoubi, Sarkis Mazmanian and Dennis Kasper in 2009 and is headquartered in Boston, MA. | - |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 5 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Dennis Kasper
- Réseau Personnel
